(Total Views: 638)
Posted On: 11/09/2021 9:47:15 PM
Post# of 155692
Look at the Amended Complaint filed today by CytoDyn on the Amarex case. Interesting is the direct interaction between CytoDyn and NSF International (the company that bought Amarex), at the end of the Amarex/CytoDyn relationship.
Sounds like Recknor is the one that caught these problems and went forward to fix them, including by contacting NSF directly. Also, all does not seem hunky dorky in NSF/Amarexville:
What company (NSF) tells their client (CytoDyn) not to talk to the actual vendor involved (Amarex) about issues like this? Were NSF and Amarex keeping secrets from each other?
Oh, and the next filing after this Amended Complaint (same day) was a letter that there are imminent settlement discussions and the case may settle.
Sounds like Recknor is the one that caught these problems and went forward to fix them, including by contacting NSF directly. Also, all does not seem hunky dorky in NSF/Amarexville:
Quote:
47. On June 8, 2021, Lush emailed Dr. Recknor and introduced himself as the “Global VP of NSF Health Sciences which includes Amarex.” Lush stated that he had engaged in “detailed discussions” with both Kevan Lawlor—NSF International’s CEO—and Chestnut about CytoDyn’s issues with Amarex, and Lush asked Dr. Recknor not to disclose their discussion to Amarex.
What company (NSF) tells their client (CytoDyn) not to talk to the actual vendor involved (Amarex) about issues like this? Were NSF and Amarex keeping secrets from each other?
Oh, and the next filing after this Amended Complaint (same day) was a letter that there are imminent settlement discussions and the case may settle.
(16)
(0)
